| Trial ID: | L3860 |
| Source ID: | NCT00995995
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Rosiglitazone
|
| Outcome Measures: |
Primary: Cost-effectiveness of rosiglitazone, From literature |
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
7641
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2008-10
|
| Completion Date: |
2009-02
|
| Results First Posted: |
|
| Last Update Posted: |
2017-05-30
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00995995
|
